Sandoz Of Novartis AG (NYSE:NVS) Acquires Antibiotics Of GlaxoSmithKline Plc (NYSE:GSK) For $500 Million

Novartis AG (NYSE:NVS)’s Sandoz entered a deal with GlaxoSmithKline Plc (NYSE:GSK) to acquire the established antibiotic brands like Fortum, Zinacef, and Zinnat for $350 million. GlaxoSmithKline will also receive milestone payments of up to $150 million. The deal will be closed by the end of this year. Sandoz decided to purchase antibiotics brands after it […]

Novartis AG (NYSE:NVS) Reports First REACH3 Study Data Showing Jakavi®’s Improving Patients Outcomes In chronic GvHD

Novartis AG (NYSE:NVS) has announced its third phase REACH3 study results, which showed that Jakavi® significant failure-free survival improvements in patients with steroid-refractory chronic graft-versus-host disease (GvHD) relative to best available therapy (BAT). Novartis reports positive REACH3 results of Jakavi in chronic GvHD The company presented the REACH3 results at the Annual 62nd American Society […]

Novartis AG (NYSE:NVS) Fires Leading Scientists Over Claims Of Gene Therapy Data Manipulation

The gene therapy division of Novartis AG (NYSE:NVS) will be missing the services of two of the company’s top scientists. Brian Kaspar and Allan Kaspar are the exiting scientists. Novartis decided to fire them after it learnt that they were involved in manipulation of gene therapy data. The Kaspars scandal The company’s CEO, Vas Narasimhan, […]

Novartis AG (NYSE:NVS) Announces New Clinical Study Updates at the ASCO 2019 Meeting

Novartis AG (NYSE:NVS) posted new clinical study updates in NSCLC at the recently held ASCO 2019 Annual Meeting. This comprised primary efficacy data from the GEOMETRY mono-1 Phase 2 clinical study. It showed that INC280 comes as a potential treatment alternative for subjects with metastatic or locally advanced NSCLC that has MET exon-14 skipping mutation. […]

Allergan, Inc. (NYSE:AGN) Loses Latisse Eyelash Ruling; Rejects Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Offer

Boston, MA 06/11/2014 (wallstreetpr) – Allergan, Inc. (NYSE:AGN), the Botox wrinkle therapy maker, lost a ruling in the appeals court which will cause generic versions of the company’s Latisse eyelash medicine enter the marketplace. Ruling Rejected Allergan, Inc. (NYSE:AGN) and Duke University owned two patents on its drug Latisse but as per the website posting, […]